Search clinical trials for: BRCA1/2 Mutation

Total 50354 results

University of Pennsylvania
Inovio Pharmaceuticals

Recruiting

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

BRCA1/2 Mutation

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

BRCA and NACT in TNBC Patients (Light-Bright)

Triple-Negative Breast Cancer

Italy
Memorial Sloan Kettering Cancer Center
Phenogen Sciences

Recruiting

Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations

Genetic Testing | BRCA1/2

United States
Cancer Trials Ireland

Active, not recruiting

Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Serous Ovarian Tumor | Endometrioid Carcinoma Ovary

Ireland
Centre Georges Francois Leclerc

Not yet recruiting

Use of an Ultra-rapid BRCA1/2 Status Screening Test in Theranostic Indication: Performance and Interest for Patients and Practitioners (TURBO)

Breast Cancer
AstraZeneca

Completed

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

HER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 Mutations

Italy, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
White Plains Hospital

Recruiting

Pancreatic Cancer Early Detection Program (PCEDP)

Pancreatic Cancer | Pancreatic Adenocarcinoma | Lynch Syndrome | Pancreas Cancer | HNPCC | Familial Pancreatic Cancer | Hereditary Pancreatitis | BRCA 1/2 | FAMMM | Familial Atypical Multiple Mole Melanoma | Peutz Jeghers Syndrome

United States
Alexandru Eniu
Iuliu Hatieganu University of Medicine and Pharmacy

Completed

BRCA1 and BRCA2 Mutation in Romanian Population: a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival

To Determine the Prevalence, Penetrance of BRCA1 and BRCA2 Mutations in Romanian Womens With Breast or Ovarian Cancer

Romania
Abramson Cancer Center at Penn Medicine

Recruiting

BRCA1/2 Flu Vaccine

BRCA1 Mutation | BRCA2 Mutation

United States
Institut Paoli-Calmettes

Unknown

Triple Negative Breast Cancer: Study of Molecular and Genetic Factors

Breast Cancer

France
Data Collection Analysis Business Management
PAS Research Services

Unknown

Increase Surveillance for Breast and Ovarian Cancers, Also to Determine Targeted Risk-reducing and Preventative Strategies

Hereditary Cancer

United States
University Health Network, Toronto

Terminated

Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.

Ovarian Cancer

Canada
German Breast Group
AstraZeneca

Completed

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (GeparOla)

Breast Cancer | Triple Negative Breast Neoplasms | HRpos Breast Neoplasms | BRCA 1 /2 and / or HRD

Germany
Lund University

Completed

Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer (BRCAsearch)

Hereditary Breast Cancer

Sweden
AstraZeneca

Completed

Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients (CHRISTELLE)

Ovarian Neoplasms

Japan
Pamela Munster
National Cancer Institute (NCI)

Recruiting

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States
Erasmus Medical Center

Recruiting

Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia? (PROFAS)

Seroma | BRCA1/2 Mutation | Bilateral Prophylactic Mastectomy | Pectoral Fascia

Netherlands
University of Oxford
AstraZeneca

Completed

Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (OCTOVA)

Ovarian Cancer

United Kingdom
Abramson Cancer Center of the University of Pennsylvania

Completed

Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study

BRCA1/2 Negative

United States
University Hospital, Montpellier

Completed

Management of Women With BRCA1/2 Mutation

BRCA1 Mutation | BRCA2 Mutation

France
National Human Genome Research Institute (NHGRI)
Johns Hopkins Bloomberg School of Public Health

Completed

Adaptation to Living With a BRCA1/2 Mutation

Cancer Genetics

United States
University of Utah
National Cancer Institute (NCI)

Completed

Risk Education and Assessment for Cancer Heredity (REACH)

Breast Cancer | Ovarian Cancer | Genetic Predisposition

United States
Fudan University

Unknown

Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer

Breast Cancer

China
Chinese Anti-Cancer Association

Unknown

The Registration Program of BRCA1/2 Gene (RCA)

Breast Cancer

China
Sun Yat-sen University

Recruiting

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Metastatic Castration-resistant Prostate Cancer

China
National Cancer Institute (NCI)

Completed

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

BRCA1 Gene | BRCA2 Gene

United States
Institut Cancerologie de l'Ouest

Recruiting

Women at Risk of Breast Cancer and OLFM4

Hereditary Breast and Ovarian Cancer Syndrome

France
Karolinska Institutet

Completed

BRCA1/2 and Effect of Mifepristone on the Breast

Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2

Sweden
Mayo Clinic

Enrolling by invitation

GENetic Risk Estimation of Breast Cancer Prior to Decisions on Preventive Therapy Uptake, Risk Reducing Surgery or Intensive Imaging Surveillance (GENRE2)

Breast Cancer

United States
Technical University of Munich
University of Cologne; University of Leipzig; University Hospital Schleswig-Holstein and other collaborators

Recruiting

Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers (LIBRE-2)

Hereditary Breast and Ovarian Cancer

Germany
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation (Gen-eva)

BRCA-Associated Breast Carcinoma

Italy
Columbia University

Recruiting

Pancreatic Cancer Genetics

Pancreatic Cancer

United States
Columbia University

Terminated

Validation of a Mouse Model of Pancreatic Carcinogenesis

Pancreatic Cancer

United States
AstraZeneca
Merck Sharp & Dohme LLC; NRG Oncology; Breast International Group; Myriad Genetic... and other collaborators

Active, not recruiting

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Breast Cancer

United States, Austria, Italy, Spain, Sweden, United Kingdom, Belgium, Poland, France, Switzerland, Canada, Germany, Korea, Republic of, Netherlands, Japan, China, Taiwan, Australia, Argentina, Israel, Hungary, Portugal, Iceland, Puerto...
Technical University of Munich

Completed

Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers (LIBRE)

Hereditary Breast and Ovarian Cancer

Germany
Heidelberg University

Completed

Feasability Study of Removing the Ovaries and Fallopian Tubes (TG-Adnex)

Ovarian Diseases

Germany
Memorial Sloan Kettering Cancer Center
Memorial Health University Medical Center

Completed

BRCA1 Haploinsufficiency and Gene Expression

BRCA1 Mutations

United States
University of Malaya
Pfizer; Cancer Research Malaysia; Pantai Hospital Kuala Lumpur; Hospital Sultan...

Recruiting

Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Triple Negative Breast Cancer | HRD 100 Gene Expression High

Malaysia
Weill Medical College of Cornell University
Basser Research Center for BRCA

Recruiting

FaCT Trial (Facilitated Cascade Testing Trial)

BRCA1 Mutation | BRCA2 Mutation

United States
University of Pennsylvania

Recruiting

Evaluating Cascade Communication Methods (ECHO)

BRCA1 Mutation | BRCA2 Mutation

United States
Azienda Ospedaliera Universitaria Policlinico Paolo...

Unknown

BRCA Main Home Nutritional Intervention-random Study

BRCA1 Mutation | BRCA2 Mutation

Italy
Abramson Cancer Center at Penn Medicine

Recruiting

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

Pancreatic Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC With BRCA Gene Mutation

Early-stage Triple-negative Breast Cancer With BRCA1/2 Mutations

China
Dana-Farber Cancer Institute
AstraZeneca

Withdrawn

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Recurrent Metastatic Melanoma

United States
National Cancer Institute (NCI)

Terminated

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; University of California, Los Angeles; Dana-Farber... and other collaborators

Active, not recruiting

BRCA Founder OutReach (BFOR) Study (BFOR)

BRCA1 Mutation | BRCA2 Mutation

United States
Rabin Medical Center

Unknown

The Link Between BRCA Mutation and Endothelial Function

BRCA1 Gene Mutation | BRCA2 Gene Mutation

Israel
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Completed

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO)

Epithelial Ovarian Cancer

Denmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
Impact Therapeutics, Inc.

Unknown

Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer (SABRINA)

Ovarian Cancer

China
European Institute of Oncology

Completed

Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing (BRCA-MEN)

BRCA1 Mutation | BRCA2 Mutation | Psychosocial Factors

Italy

Search clinical trials for: BRCA1/2 Mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations